Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Key Event: On April 21, 2006, the Company consummated the acquisition of Guidant Corporation for an aggregate purchase price of approximately $28.4 billion. This transaction significantly diversified Boston Scientific's revenue streams into the Cardiac Rhythm Management (CRM) market. Prior to the acquisition, Abbott Laboratories acquired Guidant's vascular intervention and endovascular businesses, agreeing to share drug-eluting stent technology with Boston Scientific.
Key Financial Metrics
| Financial Metric (in millions) | Three Months Ended June 30, 2006 | Three Months Ended June 30, 2005 | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|---|---|
| Net Sales | $2,110 | $1,617 | $3,730 | $3,232 |
| Gross Profit | $1,433 | $1,260 | $2,679 | $2,531 |
| Gross Margin % | 67.9% | 77.9% | 71.8% | 78.3% |
| Operating Income (Loss) | $(3,925) | $326 | $(3,428) | $839 |
| Net Income (Loss) | $(4,262) | $205 | $(3,930) | $563 |
| Diluted EPS | $(3.21) | $0.24 | $(3.66) | $0.67 |
| Cash from Operating Activities | N/A | N/A | $999 | $680 |
| Total Debt (Gross) | $8,898 | $2,020 | $8,898 | $2,020 |
| Net Debt | $7,741 | $1,172 | $7,741 | $1,172 |
Note: Debt figures represent outstanding borrowings at period end. Operating cash flow is provided for the six-month period only.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30% in the quarter and 15% in the six-month period compared to the prior year, primarily driven by the inclusion of Guidant results (approx. $474 million in sales for the quarter).
- Significant Losses: The Company reported a net loss of $4.26 billion for the quarter, compared to net income of $205 million in the prior year. This was primarily due to non-cash purchase accounting adjustments of $4.42 billion, including $4.12 billion in purchased research and development (PR&D) and inventory step-up charges related to the Guidant acquisition.
- Debt Expansion: To finance the Guidant acquisition, gross debt increased from $2.0 billion to $8.9 billion. This included a $5.0 billion term loan, a $900 million loan from Abbott, and $1.2 billion in new senior notes.
- Margin Compression: Gross margin decreased by 10 percentage points in the quarter, largely due to the step-up in value of acquired Guidant inventory sold ($185 million charge) and costs associated with Guidant product recalls.
- Amortization: Amortization expense surged to $165 million in the quarter (from $36 million) due to the amortization of intangible assets acquired from Guidant.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- CRM Market Recovery: Management expects the Cardiac Rhythm Management (CRM) market to recover but notes that growth rates in Q2 2006 were below historical levels due to Guidant's prior product recalls and field actions. The Company is focused on regaining physician confidence.
- Product Launches: The Company plans to launch the TAXUS Liberté stent system in the U.S. in the first half of 2007 and various Frontier-based CRM products within 12 to 36 months, pending regulatory approval.
- Integration: The Company anticipates incurring integration and restructuring costs. No assurances are made that efficiencies will offset these costs over time.
Risks and Contingencies
- FDA Warning Letters: Both legacy Boston Scientific and Guidant received FDA warning letters regarding manufacturing quality systems and record-keeping. The Company is implementing "Project Horizon" to remediate these issues, with a target for re-inspection in Q1 2007. Failure to resolve these could lead to product seizures or injunctions.
- Product Recalls: In June 2006, the Company announced a retrieval of specific pacemakers and defibrillators due to a supplier's low-voltage capacitor issue. Additionally, Guidant had previously faced significant field actions regarding defibrillators and pacemakers.
- Legal Proceedings: The Company is involved in significant intellectual property litigation with competitors (e.g., Johnson & Johnson, Medtronic, St. Jude Medical). It is also facing increased product liability and securities litigation following the Guidant acquisition. The accrual for legal matters increased to $381 million.
- Investment Writedowns: The Company recorded $67 million in writedowns in Q2 2006 related to strategic alliances, primarily a vascular sealing portfolio company.
Unusual Items
- Purchased R&D: A one-time charge of $4.12 billion was recorded for in-process R&D acquired from Guidant.
- AAA Program Cancellation: The Company cancelled the TriVascular AAA stent-graft program, resulting in a $20 million R&D charge, $10 million severance, and a $23 million amortization charge, partially offset by a $67 million credit to PR&D.
- Abbott Transaction Adjustment: An $87 million loss was recorded for the fair value adjustment of the "sharing of proceeds" feature related to Abbott's purchase of Boston Scientific stock.
Investor Verification Checklist
- Debt Covenants: Verify compliance with debt covenants (Debt/Pro Forma EBITDA < 4.5x through 2007; Interest Coverage > 3.0x). The Company reported compliance as of June 30, 2006.
- FDA Resolution Timeline: Monitor the progress of remediation efforts for the FDA warning letters and the scheduled re-inspection dates to assess potential operational disruptions.
- CRM Market Share: Track the recovery of Guidant's market share in the CRM sector and the impact of the recent capacitor-related retrieval on sales.
- Legal Accruals: Review updates on the $381 million legal accrual and the status of major patent litigations (e.g., Johnson & Johnson, Medtronic) which could result in material damages or injunctions.
- Integration Costs: Assess whether realized synergies are sufficient to offset the significant integration and restructuring costs incurred post-acquisition.